PLK1 and melanoma: To determine whether a transcriptional signature is associated with the capacity of cells to resist PLK1 inhibition and mount a pro-inflammatory response, we selected melanoma cell lines based on their CXCL8 induction pattern in response to BI-D1870 treatment (Fig 1D) and performed GSEA on the corresponding publicly available RNA-seq dataset for each cell line (Fig 6A).